Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer

被引：0
|
作者：
Miano, S. T. [1 ]
Rossi, G. [1 ]
Marsili, S. [1 ]
Petrioli, R. [1 ]
Pascucci, A. [1 ]
Francini, G. [1 ]
机构：
[1] Uoc Oncol Med Scotte, Siena, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A67
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [31] Apatinib plus vinorelbine: A novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.
    Yuan, Peng
    Zhu, Anjie
    Yue, Jian
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] nab-paclitaxel (nab-P) plus nivolumab (Nivo) in human epidermal growth factor receptor 2 (HER2)-negative recurrent metastatic breast cancer (MBC)
    Waterhouse, D.
    Gutierrez, M.
    Bekaii-Saab, T.
    DeRosa, W.
    Wainberg, Z.
    George, B.
    Fraser, C. Duval
    Ko, A.
    Pierce, D. W.
    Stergiopoulos, S.
    Soliman, H.
    CANCER RESEARCH, 2016, 76
  • [33] Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy
    Nakamoto, Shogo
    Watanabe, Junichiro
    Ohtani, Shoichiro
    Morita, Satoshi
    Ikeda, Masahiko
    IN VIVO, 2020, 34 (03): : 1377 - 1386
  • [34] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
    Pizzuti, Laura
    Sergi, Domenico
    Sperduti, Isabella
    Di Lauro, Luigi
    Mazzotta, Marco
    Botti, Claudio
    Izzo, Fiorentino
    Marchetti, Luca
    Tomao, Silverio
    Marchetti, Paolo
    Natoli, Clara
    Grassadonia, Antonino
    Gamucci, Teresa
    Mentuccia, Lucia
    Magnolfi, Emanuela
    Vaccaro, Angela
    Cassano, Alessandra
    Rossi, Ernesto
    Botticelli, Andrea
    Sini, Valentina
    Sarobba, Maria G.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Astone, Antonio
    Michelotti, Andrea
    De Angelis, Claudia
    Bertolini, Ilaria
    Angelini, Francesco
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    Giordano, Antonio
    Barba, Maddalena
    Vici, Patrizia
    CANCER BIOLOGY & THERAPY, 2018, 19 (04) : 328 - 334
  • [35] nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
    Glueck, Stefan
    CLINICAL BREAST CANCER, 2014, 14 (04) : 221 - 227
  • [36] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Hugo Herrscher
    Michel Velten
    Julie Leblanc
    Michal Kalish-Weindling
    Cathie Fischbach
    Delphine Exinger
    Xavier Pivot
    Thierry Petit
    Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
  • [37] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
  • [38] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
    Herrscher, Hugo
    Velten, Michel
    Leblanc, Julie
    Kalish-Weindling, Michal
    Fischbach, Cathie
    Exinger, Delphine
    Pivot, Xavier
    Petit, Thierry
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376
  • [39] Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.
    Lo, S. S.
    Guo, R.
    Czaplicki, K. L.
    Robinson, P. A.
    Gaynor, E.
    Barhamand, F. B.
    Schulz, W. C.
    Kash, J. J.
    Horvath, L. E.
    Bayer, R. A.
    Petrowsky, C.
    De la Torre, R.
    Park, J. H.
    Albain, K. S.
    CANCER RESEARCH, 2012, 72
  • [40] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345